Johnson & Johnson Price Target Raised to $253 as J&J Direct Launches
On March 3 Bank of America raised Johnson & Johnson’s target to $253 from $227, citing updated long-term revenue estimates for pipeline assets Tecvayli and Inlexzo. On March 5 the company launched J&J Direct, a platform selling Invokana, Invokamet and Xarelto to uninsured patients under its $55 billion investment plan.
1. Bank of America Raises Price Target
On March 3 Bank of America raised its price target for Johnson & Johnson to $253 from $227, maintaining a neutral rating while updating long-term revenue estimates to reflect improved projections for late-stage assets.
2. Pipeline Assets Spotlight
Analyst commentary highlighted Tecvayli’s strong clinical data and its potential to extend treatment duration for Darzalex, alongside Inlexzo’s anticipated market entry, as key drivers of J&J’s revenue outlook.
3. Launch of J&J Direct Platform
On March 5 the company introduced J&J Direct, an online platform allowing uninsured or out-of-pocket patients in the US to purchase Invokana, Invokamet and Xarelto directly, supporting its commitment to a $55 billion domestic investment plan over four years.